JP7366057B2 - 合成ｒｉｇ－ｉ様受容体アゴニスト - Google Patents

合成ｒｉｇ－ｉ様受容体アゴニスト Download PDF

Info

Publication number
JP7366057B2
JP7366057B2 JP2020557150A JP2020557150A JP7366057B2 JP 7366057 B2 JP7366057 B2 JP 7366057B2 JP 2020557150 A JP2020557150 A JP 2020557150A JP 2020557150 A JP2020557150 A JP 2020557150A JP 7366057 B2 JP7366057 B2 JP 7366057B2
Authority
JP
Japan
Prior art keywords
agonist
rlr
polynucleotide
sequence
inosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020557150A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521780A (ja
JP2021521780A5 (enExample
Inventor
アーサー エム． クリーグ，
アーロン ジェイ モリス，
Original Assignee
チェックメイト ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チェックメイト ファーマシューティカルズ， インコーポレイテッド filed Critical チェックメイト ファーマシューティカルズ， インコーポレイテッド
Publication of JP2021521780A publication Critical patent/JP2021521780A/ja
Publication of JP2021521780A5 publication Critical patent/JP2021521780A5/ja
Priority to JP2023142852A priority Critical patent/JP7847568B2/ja
Application granted granted Critical
Publication of JP7366057B2 publication Critical patent/JP7366057B2/ja
Priority to JP2025094028A priority patent/JP2025120300A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/331—Universal or degenerate base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020557150A 2018-04-19 2019-04-19 合成ｒｉｇ－ｉ様受容体アゴニスト Active JP7366057B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023142852A JP7847568B2 (ja) 2018-04-19 2023-09-04 合成ｒｉｇ－ｉ様受容体アゴニスト
JP2025094028A JP2025120300A (ja) 2018-04-19 2025-06-05 合成ｒｉｇ－ｉ様受容体アゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862659999P 2018-04-19 2018-04-19
US62/659,999 2018-04-19
PCT/US2019/028343 WO2019204743A1 (en) 2018-04-19 2019-04-19 Synthetic rig-i-like receptor agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023142852A Division JP7847568B2 (ja) 2018-04-19 2023-09-04 合成ｒｉｇ－ｉ様受容体アゴニスト

Publications (3)

Publication Number Publication Date
JP2021521780A JP2021521780A (ja) 2021-08-30
JP2021521780A5 JP2021521780A5 (enExample) 2022-04-20
JP7366057B2 true JP7366057B2 (ja) 2023-10-20

Family

ID=66647446

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020557150A Active JP7366057B2 (ja) 2018-04-19 2019-04-19 合成ｒｉｇ－ｉ様受容体アゴニスト
JP2023142852A Active JP7847568B2 (ja) 2018-04-19 2023-09-04 合成ｒｉｇ－ｉ様受容体アゴニスト
JP2025094028A Pending JP2025120300A (ja) 2018-04-19 2025-06-05 合成ｒｉｇ－ｉ様受容体アゴニスト

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023142852A Active JP7847568B2 (ja) 2018-04-19 2023-09-04 合成ｒｉｇ－ｉ様受容体アゴニスト
JP2025094028A Pending JP2025120300A (ja) 2018-04-19 2025-06-05 合成ｒｉｇ－ｉ様受容体アゴニスト

Country Status (7)

Country Link
US (3) US10907161B2 (enExample)
EP (1) EP3781689A1 (enExample)
JP (3) JP7366057B2 (enExample)
CN (2) CN119286871A (enExample)
AU (3) AU2019255370B2 (enExample)
CA (1) CA3093715A1 (enExample)
WO (1) WO2019204743A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN119286871A (zh) 2018-04-19 2025-01-10 查美特制药公司 合成rig-i样受体激动剂
US11542505B1 (en) 2018-04-20 2023-01-03 Merck Sharp & Dohme Llc Substituted RIG-I agonists: compositions and methods thereof
EP3810151B1 (en) 2018-06-20 2025-08-06 Yale University Rig-i agonists and treatments using same
EP3863675A4 (en) * 2018-10-09 2023-09-06 Yale University RIG-I AGONISTS AND METHODS OF USE THEREOF
CA3155202A1 (en) * 2019-10-23 2021-04-29 Arthur M. Krieg Synthetic rig-i-like receptor agonists
US11786545B2 (en) * 2020-12-09 2023-10-17 Yale University Compositions and methods for treating SARS-CoV-2 infection
KR20240043747A (ko) 2021-07-02 2024-04-03 예일 유니버시티 암을 치료하기 위한 조성물 및 방법
JP2024532621A (ja) 2021-08-31 2024-09-05 イエール ユニバーシティ がんを治療するための組成物および方法
AU2023228912A1 (en) 2022-03-03 2024-09-19 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
CN115969971B (zh) * 2022-11-24 2023-08-18 珠海恩科生物科技有限公司 组合物在制备治疗肿瘤的药物中的应用
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding
CN119371516B (zh) * 2024-11-01 2025-08-12 复旦大学 一种抗肿瘤的短肽、药物组合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159990A1 (en) 2013-03-13 2014-10-02 Yale University Interferon production using short rna duplexes
WO2016011324A2 (en) 2014-07-18 2016-01-21 Oregon Health & Science University 5'-triphosphate oligoribonucleotides

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
EP0563091A1 (en) 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
FR2693813B1 (fr) 1992-07-20 1994-08-19 Commissariat Energie Atomique Procédé de réalisation d'une image de référence synthétisée à partir de données contenues dans une base de données CAO.
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
CN1185811A (zh) 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
JP3944914B2 (ja) 1996-10-14 2007-07-18 セイコーエプソン株式会社 累進多焦点レンズの製造方法
WO2000023955A1 (en) 1998-10-21 2000-04-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Virus-like particles for the induction of autoantibodies
MXPA01005389A (es) 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
JP4713809B2 (ja) 2000-04-07 2011-06-29 ユニバーシティ オブ リードズ イノベイションズ リミテッド Ｂ型肝炎コア抗原融合タンパク質
EP1278542A2 (en) 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
ATE320493T1 (de) 2000-06-22 2006-04-15 Ucb Pharma Ltd Modifizierung des hepatitis b kernantigens
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
DE10201743C2 (de) 2002-01-18 2003-12-18 Aesculap Ag & Co Kg Intramedulläres Osteosyntheseimplantat
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
AU2003246690B2 (en) 2002-07-17 2010-03-11 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the AP205 coat protein
BR0312792A (pt) 2002-07-19 2005-05-03 Cytos Biotechnology Ag Composições de vacinas contendo séries antigênicas de amilóide beta1-6
ATE390205T1 (de) 2002-12-10 2008-04-15 Haldor Topsoe As Verfahren zur katalytischen dehydrierung und katalysator dafür
CN101675993A (zh) 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
WO2006063252A2 (en) 2004-12-09 2006-06-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
ATE515566T1 (de) 2005-05-26 2011-07-15 Cytos Biotechnology Ag Skalierbares fermentationsverfahren
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
JP2010500011A (ja) 2006-08-08 2010-01-07 ガンサー ハートマン ５’リン酸オリゴヌクレオチドの構造および使用
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
JP5721441B2 (ja) 2008-01-31 2015-05-20 キュアバック ゲーエムベーハーＣｕｒｅｖａｃ Ｇｍｂｈ 免疫賦活剤／アジュバントとしての式（Ｉ）（ＮｕＧｌＸｍＧｎＮｖ）ａで表される核酸分子及びその誘導体
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
WO2010002851A1 (en) 2008-06-30 2010-01-07 Alnylam Pharmaceuticals, Inc. Silencing and rig-1 activation by dual function oligonucleotides
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
AU2009288078B2 (en) 2008-09-02 2014-10-30 Alnylam Pharmaceuticals, Inc. Synthetic methods and derivatives of triphosphate oligonucleotides
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
JP2014532400A (ja) 2011-10-31 2014-12-08 リボックス・ゲーエムベーハー 免疫賦活用の二本鎖ｒｎａ
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
WO2013097965A1 (en) 2011-12-30 2013-07-04 Riboxx Gmbh Triphosphate-containing double-stranded rna for immunostimulation
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
WO2013180295A1 (ja) 2012-06-01 2013-12-05 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US20140287023A1 (en) 2013-02-11 2014-09-25 Mcgill University 5'-triphosphate oligoribonucleotides
WO2014164253A1 (en) 2013-03-09 2014-10-09 Moderna Therapeutics, Inc. Heterologous untranslated regions for mrna
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014169049A1 (en) * 2013-04-09 2014-10-16 Duke University 2' fluoro-modified rnas as immunostimulators
US9775894B2 (en) 2013-07-09 2017-10-03 University Of Washington Through Its Center For Commercialization Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
WO2015038746A1 (en) 2013-09-11 2015-03-19 Georgia Tech Research Corporation Compositions and methods for inhibiting gene expression
EP3083962B1 (en) 2013-12-16 2021-08-18 RiboxX GmbH Double-stranded polyc:poly(g/i) rna for immunostimulation and cancer treatment
US10273484B2 (en) 2014-03-24 2019-04-30 Riboxx Gmbh Double-stranded RNA conjugates and their use
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
AU2015224518B2 (en) 2014-07-15 2017-03-09 Drifire, Llc Lightweight, dual hazard fabrics
CA2971734C (en) 2014-12-22 2025-11-18 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
WO2017121494A1 (en) 2016-01-15 2017-07-20 Riboxx Gmbh 5'-triphosphated short immunostimulatory nucleotides, oligonucleotides and polynucleotides
EP3436031A4 (en) * 2016-04-01 2019-09-18 Vycellix, Inc. Novel RNA construct and method of use therefor for increasing the therapeutic effects of cytotoxic cells and stem cells
CN109414461A (zh) 2016-04-26 2019-03-01 曲生物制品公司 治疗性地触发靶组织中的先天性免疫应答
WO2017221076A1 (en) 2016-06-24 2017-12-28 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
WO2018172546A1 (en) * 2017-03-24 2018-09-27 Rigontec Gmbh Method for designing rig-i ligands
US10736957B2 (en) * 2017-12-19 2020-08-11 President And Fellows Of Harvard College Enhanced immunogenicity of mRNA with co-encoded adjuvant sequences
JP7386161B2 (ja) * 2017-12-19 2023-11-24 ブレイズ バイオサイエンス， インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
BR112020020479A2 (pt) 2018-04-09 2021-01-12 Checkmate Pharmaceuticals Empacotamento de oligonucleotídeos em partículas similares a vírus
CN119286871A (zh) 2018-04-19 2025-01-10 查美特制药公司 合成rig-i样受体激动剂
EP3791689A1 (en) 2018-05-08 2021-03-17 Telefonaktiebolaget Lm Ericsson (Publ) Methods and nodes for enabling management of traffic
EP3810151B1 (en) * 2018-06-20 2025-08-06 Yale University Rig-i agonists and treatments using same
CA3155202A1 (en) 2019-10-23 2021-04-29 Arthur M. Krieg Synthetic rig-i-like receptor agonists
CN115376873A (zh) 2021-05-18 2022-11-22 江苏鲁汶仪器有限公司 离子源装置及其使用方法和真空处理系统

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159990A1 (en) 2013-03-13 2014-10-02 Yale University Interferon production using short rna duplexes
WO2016011324A2 (en) 2014-07-18 2016-01-21 Oregon Health & Science University 5'-triphosphate oligoribonucleotides

Also Published As

Publication number Publication date
US20200063141A1 (en) 2020-02-27
EP3781689A1 (en) 2021-02-24
JP2023158048A (ja) 2023-10-26
JP2021521780A (ja) 2021-08-30
US12123003B2 (en) 2024-10-22
US20210207148A1 (en) 2021-07-08
US10907161B2 (en) 2021-02-02
JP7847568B2 (ja) 2026-04-17
US20240368607A1 (en) 2024-11-07
AU2023229532A1 (en) 2023-09-28
WO2019204743A1 (en) 2019-10-24
AU2024287196A1 (en) 2025-01-23
AU2023229532B2 (en) 2024-09-26
CN112105733A (zh) 2020-12-18
CA3093715A1 (en) 2019-10-24
JP2025120300A (ja) 2025-08-15
AU2019255370A1 (en) 2020-09-17
CN119286871A (zh) 2025-01-10
CN112105733B (zh) 2024-10-29
AU2019255370B2 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
JP7847568B2 (ja) 合成ｒｉｇ－ｉ様受容体アゴニスト
JP6748629B2 (ja) ５’リン酸オリゴヌクレオチドの構造および使用
JP6885867B2 (ja) 組合せ腫瘍免疫療法
AU2011329668B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US10066230B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
JP2025138811A (ja) 合成ｒｉｇ－ｉ様受容体アゴニスト
EP4719437A1 (en) Connector modified synthetic rig-i agonists and methods of using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231010

R150 Certificate of patent or registration of utility model

Ref document number: 7366057

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150